Gene Therapy Setbacks and Strategic Shifts in Biotech

About this episode

This episode discusses recent setbacks in gene therapy and strategic shifts in the biotech industry.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. This week, we delve into a series of compelling stories that are shaping the future of drug development, therapeutic innovation, and patient care. The gene therapy sector is currently under the spotlight, with Johnson & Johnson handing back the rights to botaretigene sparoparvovec to MeiraGTx following a phase 3 trial failure. This underscores the inherent ...

People in this episode

Host: Pharma and BioTech News

Topics covered

• gene therapy
• biotech
• drug development
• therapeutic innovation
• patient care

Keywords

• gene therapy
• biotech
• Johnson & Johnson
• MeiraGTx
• drug development
• phase 3 trial
• therapeutic innovation

Mentioned in this episode

Organizations: Johnson & Johnson, MeiraGTx

Products: botaretigene sparoparvovec

More episodes of Pharma and BioTech Daily

• Takeda's Zasocitinib Beats Sotyktu in Phase 3 Trial | Pharma and Biotech Daily · June 12, 2026 · 5 min
• Pfizer CEO Rethinks Germany Investments Amid Reform Concerns | Pharma and Biotech Daily · June 11, 2026 · 5 min
• Merck & Gilead's HIV Pill Breakthrough: Phase 3 Success! | Pharma and Biotech Daily · June 10, 2026 · 5 min
• Eli Lilly's Retatrutide Breakthrough: 30.3% Weight Loss Success | Pharma and Biotech Daily · June 9, 2026 · 5 min
• Pfizer & Chai AI Breakthrough: $1.675B Gilead Deal | Pharma and Biotech Daily · June 8, 2026 · 5 min
• Eli Lilly & Boehringer Cut $1B+ Investments in Germany | Pharma and Biotech Daily · June 5, 2026 · 5 min